Perspective Therapeutics and Merck collaborate to supply [212Pb]PSV359
Perspective Therapeutics announced a clinical collaboration and supply agreement with Merck to evaluate [212Pb]PSV359 in combination with Keytruda (pembrolizumab) in FAP-α positive solid tumors.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.